Effect of baseline FVC on lung function decline with nintedanib in patients with IPF
Published: Sep 1, 2015
Abstract
Background: The efficacy and safety of nintedanib 150 mg twice daily (bid) in patients with idiopathic pulmonary fibrosis (IPF) were assessed in the two replicate, 52-week, Phase III INPULSIS® trials. Patients with forced vital capacity (FVC) ≥50% predicted were eligible to participate. Compared with placebo, nintedanib significantly reduced the annual rate of decline in FVC, the primary endpoint, in both trials. Aim: To...
Paper Details
Title
Effect of baseline FVC on lung function decline with nintedanib in patients with IPF
Published Date
Sep 1, 2015
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History